Title of Invention: MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES Abstract: The present disclosure relates to compositions and methods for combinatorial assessment of nanoscale droplets, as specifically exemplified by massively parallel assessment of spatially-directed (while agnostic as to precise droplet content) combinations of droplets harboring distinct and independently identifiable microbial types and/or chemical compounds or mixtures. More particularly, the disclosure relates to a platform and methodologies for identifying advantageous (including synergistic, additive, etc.) microbial interactions and/or chemical compound or mixture interactions with microbes in a manner that allows for binary, trinary, etc. combinatorial assessments to be performed across a range of many discrete input types of microbes (e.g., 6-16 or more discrete input microbial types), to an extent capable of approaching comprehensive sampling and measurement of microbial community combinations from a selected panel of microbial inputs, optionally also in the presence of chemical compounds or mixtures (e.g., test compounds or mixtures for antimicrobial effect). Detailed Description: CROSS REFERENCE TO RELATED APPLICATION This application claims the benefit of U.S. Provisional Application No. 62/841,546, filed May 1, 2019, entitled “Massively Parallel On-Chip Construction of Synthetic Microbial Communities,” the entire contents of which are incorporated herein by reference. FIELD OF THE DISCLOSURE The disclosure relates to compositions and methods for combinatorial assessment of nanoscale droplets, as specifically exemplified by massively parallel assessment of spatially-directed (though agnostic as to precise content) combinations of droplets harboring distinct and independently identifiable microbial types. More particularly, the disclosure relates to a platform and methodologies for identifying advantageous (including synergistic, additive, etc.) microbial interactions in a manner that allows for binary, trinary, etc. combinatorial assessments to be performed across a range of many discrete input types of microbes (e.g., 6-16 or more discrete input microbial types), to an extent that approaches comprehensive sampling of microbial community combinations from a selected panel of microbial inputs. BACKGROUND OF THE DISCLOSURE Microbial communities have numerous potential applications in biotechnology, agriculture, and medicine. Yet the limited accuracy with which interspecies interactions and environmental dependencies can be predicted has heretofore hindered efforts to rationally engineer beneficial consortia. Empirical screening is a complementary approach wherein synthetic communities are combinatorially constructed and assayed in high throughput. However, assembling many combinations of microbes is logistically complex and difficult to achieve on a timescale commensurate with microbial growth. Extant experimental strategies to investigate microbial community behavior have therefore been limited by the challenges posed by the combinatorial complexity of interactions between species. Accordingly, there is an urgent need for compositions and methods for identifying microbial communities possessing preferred attributes, where input microbes are selected from among even a modest panel of discrete types of microbes (e.g., 6-16 or more), in a scalable and cost-efficient manner that allows for microbial community assessment coverage to occur across a significant portion of the probability-defined complexity space (specifically, where complex microbial populations are assembled to include precisely k inputs (e.g. strains or media) selected from a larger library of n (e.g. strains or media), comprehensive assessment of such complex microbial combinations would require sampling of n-multichoose-k combinations). SUMMARY OF THE DISCLOSURE The instant disclosure is based, at least in part, upon the discovery of a platform and associated methodology that enables parallel screening of distinct combinations of input liquid samples (encapsulated in droplets, which in certain aspects encapsulate distinct microbe and/or chemical compound inputs) in a manner that both maximizes tested combinations of input samples while minimizing the number of liquid handling processes required to achieve such combinations and measure properties associated with such combinations. In certain aspects, the instant disclosure specifically provides a platform to automatically construct and test synthetic communities of microbes—optionally together with chemical compounds (e.g., test compounds)—from a set of input species, at a scale of ˜100,000 (˜105) to ˜108 or more communities per day. In one aspect, the instant disclosure provides a microfluidic screening platform that includes at least one droplet input for receiving one or more sets of droplets, each set of droplets including individual droplets each individual droplet having a single type of microbe and/or chemical compound or mixture; and an array of microwells, where each microwell is capable of receiving an individual droplet. In one embodiment, a plurality (optionally a majority) of the microwells of the array of microwells includes one and only one droplet. In another embodiment, individual droplets of the array of microwells are optically screened, and optionally optical screening of individual droplets identifies the single type of microbe and/or chemical compound or mixture present in the individual droplet. In a related embodiment, the optical screening includes measurement of luminescence and/or fluorescence, optionally where the fluorescence of one or more agents such as Alexa Fluor 488, Alexa Fluor 555, Alexa Fluor 594 and/or Alexa Fluor 647 is measured, optionally where a ratio or ratios of Alexa Fluor 488, Alexa Fluor 555, Alexa Fluor 594 and/or Alexa Fluor 647 identifies the single type of microbe present in the individual droplet. In an additional embodiment, individual droplets in user-selected adjacent microwells are merged into a single merged assay, optionally by electrocoalescence, thermal coalescence or acoustic coalescence. In a further embodiment, across the array, individual droplets in k=2-50 adjoining microwells, optionally in k=2, 3, 4, 5, 6, 7 and/or 19 adjoining microwells, are merged into single merged assays. In another embodiment, one or more attributes of the microbes and/or chemical compounds or mixtures present in each merged assay are measured via optical screening. Optionally, the optical screening includes measurement of luminescence and/or fluorescence, optionally autofluorescence, optionally in a label-free optical assay, optionally where the optical screening includes measurement of GFP, YFP and/or resorufin fluorescence. In one embodiment, the droplets including microbes and/or chemical compounds or mixtures self-assemble randomly into microwells. In another embodiment, the one or more attributes of the microbes present in each merged assay measured via optical screening include growth of the microbes, optionally growth of the microbes on a carbon source of Table 1. In an additional embodiment, each single merged assay includes two or more types of microbes and optionally three or more types of microbes, optionally where the two or more types of microbes are Achromobacter spp. (e.g., Achromobacter denitrificans, Achromobacter xylosoxidans, Achromobacter ruhlandii); Actinomadura spp. (e.g., Actinomadura luteofluorescens, Actinomadura madurae, Actinomadura pelletieri, Actinomadura viridis); Agrobacterium spp. (e.g., Agrobacterium radiobacter, Agrobacterium luteum, Agrobacterium agile, Agrobacterium rubi); Arthrobacter spp. (e.g., Arthrobacter arilaitensis, Arthrobacter chlorophenolicus, Arthrobacter aurescens); Bacillus spp. (e.g., Bacillus cereus, Bacillus subtilis, Bacillus coagulans, Bacillus psychrosaccharolyticus, Bacillus amyloliquefaciens, Bacillus lentus, Bacillus circulans, Bacillus firmus); Burkholderia spp. (e.g., Burkholderia gladioli, Burkholderia plantarii, Burkholderia cepacia); Clostridium spp. (e.g., Clostridium orbiscindens, Clostridium formicaceticum); Escherichia coli; Ewingella spp. (e.g., Ewingella americana); Flavobacterium spp. (e.g., Flavobacterium flevense, Flavobacterium aquatile, Flavobacterium saccharophilum, Flavobacterium hydatis, Flavobacterium johnsoniae); Flexibacter spp. (e.g., Flexibacter flexilis, Flexibacter columnare); Herbaspirillum frisingense; Hyphomicrobium spp. (e.g., Hyphomicrobium aestuarii); Micromonospora spp. (e.g., Micromonospora rosaria, Micromonospora facile, Micromonospora zavarzinii, Micromonospora denitrificans); Mycobacterium spp. (e.g., Mycobacterium neoaurum); Nocardia spp. (e.g., Nocardia jiangxiensis, Nocardia miyunensis); Paenibacillus spp. (e.g., Paenibacillus macquariensis, Paenibacillus macerans, Paenibacillus alvei, Paenibacillus polymyxa, Paenibacillus chibensis); Pseudomonas spp. (e.g., Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas citronellolis, Pseudomonas chlororaphis, Pseudomonas aurantiaca, Pseudomonas pseudopalustris, Pseudomonas palustris, Pseudomonas syringae, Pseudomonas veronii, Pseudomonas aurantiaca); Ralstonia spp. (e.g., Ralstonia solanacearum, Ralstonia pickettii, Ralstonia syzygii); Rhodococcus spp. (e.g., Rhodococcus erythropolis, Rhodococcus rhodochrous); Serratia spp. (e.g., Serratia marcescens, Serratia liquefaciens); Sphingomonas spp. (e.g., Sphingomonas echinoides, Sphingomonas leidyi, Sphingomonas wittichii); Streptomyces spp. (e.g., Streptomyces lividans, Streptomyces coelicolor, Streptomyces tanashiensis, Streptomyces clavuligerus, Streptomyces griseus); Venturia, Aspergillus, Podosphaera, Erysiphe, Monilinia, Uncinula, Aureobasidium, Sclerophoma, Acremonium, Actinoplanes, Agaricus, Chrysosporium, Colletotrichum, Coprinus, Cryptococcus, Filibasidum, Humicola, Magnaporthe, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Phytophthora, Piromyces, Panerochaete, Pleurotus, Pythium, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, Hemileia, Rhizoctonia, Puccinia, Coniophora, Serpula, Poria, Uromyces, Gloeophyllum, Lentinus, Coriolus, Irpex, Mucor, Botrytis, Helminthosporium, Rhynchosporiur, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia, Penicillium, Geotrichum, and/or Zymoseptoria. In certain embodiments, it is contemplated that pairwise combinations of microbe types, or even single species of microbes, can be assessed using the compositions and methods disclosed herein. In one embodiment, each single merged assay harbors two or more types of microbes and/or chemical compounds or mixtures, where at least one of the two or more types of microbes and/or chemical compounds or mixtures is a microbe. Optionally, at least one of the two or more types of microbes is a fungus. Optionally, the fungus is Venturia, Aspergilhts, Podosphaera, Erysiphe, Monilinia, Uncinula, Aureobasidium, Sclerophoma, Acremonium, Actinoplanes, Agaricus, Chrysosporium, Colletotrichum, Coprinus, Cryptococcus, Filibasidum, Humicola, Magnaporthe, Ayeliophthora, Neocallimastix, Neuroslora, Paecilomyces, Phytophthora, Piromyces, Panerochaete, Pleurotus, Pythium, Schizophvllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, Hemileia, Rhizoctonia, Puccinia, Coniophora, Serpula, Poria, Uromyces, Gloeophyllum, Lentinus, Coriolus, Irpex, Mucor, Botrytis, Helminthosporium, Rhynchosporium, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia, Penicillium, Geotrichum, and/or Zymoseptoria, In certain embodiments, the fungus is a filamentous fungus, e.g., Acremonium, Agaricus, Aspergillis (e.g., Aspergillus niger (i.e., A. niger van Tieghem ATCC® 10535™); Aspergillus fumigatus (i.e., A. fumigatus Fresenius ATCC® 969187™); Aspergillus penicillioides (i.e., A. penicillioides Spegazzini, anamorph ATCC® 42692™)), Aureobasidium, Chrysosporiurn, Coprinus, Cryptococcus, Filibasidium, Fusarium (e.g., Fusarium oxysporum (i.e., F. oxysporum Schlechtendahl ATCC® MYA-1198™)), Humicola, Magnaporthe, Mucor (e.g., Mucor circinelloides (i.e., M. circinelloides van Tieghem ATCC® 38592™)), Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium (e.g., Penicillium glabrum (i.e., P. glabrum (Wehmer) Westling ATCC® 10103™)), Piromyces, Panerochaete, Pleurotus, Schizophyllun, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, and/or Zymoseptoria. In some embodiments, at least one of the two or more types of microbes and/or chemical compounds or mixtures is a chemical compound. Optionally, the chemical compound is a small molecule. In certain embodiments, at least one of the two or more types of microbes and/or chemical compounds or mixtures is a bacterium. Optionally, the bacterium is Achromobacter spp. (e.g., Achromobacter denitrificans, Achromobacter xylosoxidans, Achromobacter ruhlandii); Actinomadura spp. (e.g., Actinomadura luteofluorescens, Actinomadura madurae, Actinomadura pelletieri, Actinomadura viridis); Agrobacterium spp. (e.g., Agrobacterium radiobacter, Agrobacterim luteum, Agrobacterium agile, Agrobacterium rubi); Arthrobacter spp. (e.g., Arthrobacter arilaitensis, Arthrobacter chlorophenolicus, Arthrobacter aurescens); Bacillus spp. (e.g., Bacillus cereus, Bacillus subtilis, Bacillus coagulans, Bacillus psychrosaccharolyticus, Bacillus amyloliquefaciens, Bacillus lentus, Bacillus circulans, Bacillus firmus); Burkholderia spp. (e.g., Burkholderia gladioli, Burkholderia plantarii, Burkholderia cepacia); Clostridium spp. (e.g., Clostridium orbiscindens, Clostridium formicaceticum); Escherichia coli; Ewingella spp. (e.g., Ewingella americana); Flavobacterium spp. (e.g., Flavobacterium flevense, Flavobacterium aquatile, Flavobacterium saccharophilum, Flavobacterium hydatis, Flavobacterium johnsoniae); Flexibacter spp. (e.g., Flexibacter flexilis, Flexibacter columnare); Herbaspirillum frisingense; Hyphomicrobium spp. (e.g., Hyphomicrobium aestuarii); Micromonospora spp. (e.g., Micromonospora rosaria, Micromonospora facile, Micromonospora zavarzinii, Micromonospora denitrificans); Mycobacterium spp. (e.g., Mycobacterium neoaurum); Nocardia spp. (e.g., Nocardia jiangxiensis, Nocardia miyunensis); Paenibacillus spp. (e.g., Paenibacillus macquariensis, Paenibacillus macerans, Paenibacillus alvei, Paenibacillus polymyxa, Paenibacillus chibensis); Pseudomonas spp. (e.g., Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas citronellolis, Pseudomonas chlororaphis, Pseudomonas aurantiaca, Pseudomonas pseudopalustris, Pseudomonas palustris, Pseudomonas syringae, Pseudomonas veronii, Pseudomonas aurantiaca); Ralstonia spp. (e.g., Ralstonia solanacearum, Ralstonia pickettii, Ralstonia syzygii); Rhodococcus spp. (e.g., Rhodococcus erythropolis, Rhodococcus rhodochrous); Serratia spp. (e.g., Serratia marcescens, Serratia liquefaciens); Sphingomonas spp. (e.g., Sphingomonas echinoides, Sphingomonas leidyi, Sphingomonas wittichii); and/or Streptomyces spp. (e.g., Streptomyces lividans, Streptomyces coelicolor, Streptomyces tanashiensis, Streptomyces clavuligerus, Streptomyces griseus). In an embodiment, each single merged assay harbors two or more types of fungi. Optionally, the two or more types of fungi are Venturia, Aspergillus, Podosphaera, Erysiphe, Monilinia, Uncinula, Aureobasidium, Sclerophoma, Acremonium, Actinoplanes, Agaricus, Chrysosporium, Colletotrichum, Coprinus, Cryptococcus, Filibasidum, Humicola, Magnaporthe, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Phytophthora, Piromyces, Panerochaete, Pleurotus, Pythium, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, Hemilea, Rhizoctonia, Puccinia, Coniophora, Serpula, Poria, Uromyces, Gloeophyllum, Lentinus, Coriolus, Irpex, Mucor, Botrytis, Helminthosporium, Rhjnchosporium, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia, Penicillium, Geotrichum, and/or Zymoseptoria. In one embodiment, at least one of the single merged assays harbors a combination of at least one fungus and at least one bacteria. Optionally, a plurality of the single merged assays harbor a combination of at least one fungus and at least one bacteria. Optionally, a majority of the single merged assays harbor a combination of at least one fungus and at least one bacteria. In an embodiment, at least one of the single merged assays harbors a combination of at least one fungus and at least one chemical compound or mixture. Optionally, a plurality of the single merged assays harbor a combination of at least one fungus and at least one chemical compound or mixture. Optionally, a majority of the single merged assays harbor a combination of at least one fungus and at least one chemical compound or mixture. In one embodiment, at least one of the single merged assays harbors a combination of at least one bacteria and at least one chemical compound or mixture. Optionally, a plurality of the single merged assays harbor a combination of at least one bacteria and at least one chemical compound or mixture. Optionally, a majority of the single merged assays harbor a combination of at least one bacteria and at least one chemical compound or mixture. In an embodiment, at least one of the single merged assays harbors a combination of at least one bacteria, at least one fungus and at least one chemical compound or mixture. Optionally, a plurality of the single merged assays harbor a combination of at least one bacteria, at least one fungus and at least one chemical compound or mixture. Optionally, a majority of the single merged assays harbor a combination of at least one bacteria, at least one fungus and at least one chemical compound or mixture. Optionally, the array of microwells includes droplets constituting at least four different types of microbe, at least five different types of microbe, optionally at least six different types of microbe, optionally at least seven different types of microbe, optionally at least eight different types of microbe, optionally at least nine different types of microbe, optionally at least ten different types of microbe, optionally at least eleven different types of microbe, optionally at least twelve different types of microbe, optionally at least thirteen different types of microbe, optionally at least fourteen different types of microbe, optionally at least fifteen different types of microbe, optionally at least sixteen different types of microbe, optionally at least seventeen different types of microbe, optionally at least eighteen different types of microbe, or optionally at least nineteen different types of microbe. In certain embodiments, each microwell of the array of microwells is approximately 80 μm to approximately 180 μm or more in diameter, approximately 80 μm to approximately 170 μm or more in diameter, approximately 125 μm to 165 μm in diameter, optionally approximately 130 μm to 160 μm in diameter, optionally approximately 135 μm to 155 μm in diameter, optionally approximately 140 μm to 150 μm in diameter, optionally approximately 145 μm to 150 μm in diameter, optionally approximately 148 μm in diameter, optionally precisely 148.2 μm in diameter. In additional embodiments, each microwell of the array of microwells is approximately 110 μm to 120 μm deep. In some embodiments, a majority of the individual droplets are of size approximately 120 μm to 150 μm in diameter, optionally 125 μm to 145 μm in diameter, optionally 130 μm to 140 μm in diameter. In certain embodiments, three or more posts encircle each microwell of the array, optionally six posts encircle each microwell of the array, optionally the posts are triangular, square, round, oval, rectangular, cylindrical or hemispherical, optionally each post is approximately 10 μm to 100 μm wide, optionally approximately 40 μm wide. Optionally, the posts are of a sufficient size to enhance loading of each of the majority of the microwells with one and only one droplet, as compared to a microfluidic screening platform lacking said posts. Another aspect of the instant disclosure provides a microfluidic screening platform that includes at least one droplet input for receiving one or more sets of droplets; and an array of microwells for receiving the droplets, where a majority of the microwells receives one and only one droplet. In one embodiment, the platform further includes a series of channels designed to trap droplets of less than a predefined diameter, where the series of channels is positioned upstream of the microarray. Optionally, the platform includes a series of 10 or more channels, optionally 15 or more channels, optionally 30 or more channels, optionally where each of the series of channels is approximately 90 μm wide. Another aspect of the instant disclosure provides a microfluidic screening platform that includes at least one droplet input for receiving one or more sets of droplets, where the one or more sets of droplets are administered to a high-pass size filter including a series of channels designed to trap droplets of less than a predefined diameter; and an array of microwells for receiving the droplets (e.g., those that transit the high-pass size filter). In one embodiment, the high-pass size filter includes a series of 10 or more channels, optionally a series of 15 or more channels, optionally a series of 30 or more channels. In certain embodiments, the high-pass size filter channels are of approximately 80 μm to 134 μm in width, optionally approximately 90 μm in width. An additional aspect of the instant disclosure provides a method of comparing pairwise or higher order complexes of droplet-encapsulated fluids in parallel, the method involving administering a variety of droplet-encapsulated fluidic compositions to a microfluidic screening platform including an array of microwells, where the microwells possess an arrangement and size that allow for a plurality of the microwells of the array of microwells to receive one and only one droplet; applying electrocoalescence, thermal coalescence or acoustic coalescence to merge droplets in user-selected adjacent microwells into a single merged assay, across the array of microwells, thereby forming an array of at least 500 independent merged assays; and comparing merged assays selected from among the at least 500 independent merged assays with one another to identify attributes of the merged assays, thereby comparing pairwise or higher order complexes of droplet-encapsulated fluidic compositions in parallel. In one embodiment, the number of independent merged assays on the platform is at least 1000, optionally at least 5000, optionally at least 10000, optionally at least 100000, optionally approximately 1,000,000 or more. In certain embodiments, the droplet-encapsulated fluids include microbes and/or chemical compounds or mixtures, optionally where the identity of the microbes and/or chemical compounds or mixtures encapsulated in an individual droplet is determined by detection of luminescent and/or fluorescent agents present in the droplet, optionally where the luminescent and/or fluorescent agents are present in a ratio that defines the identity of the microbe and/or chemical compound(s) or mixture(s) in the droplet, optionally where measurement of the luminescent and/or fluorescent agents in the droplet is performed before applying the electrocoalescence, thermal coalescence or acoustic coalescence to merge droplets in user-selected adjacent microwells into a single merged assay. Another aspect of the disclosure provides a method of performing pairwise or higher order comparisons between droplet-encapsulated fluidic compositions in parallel, the method involving administering a variety of droplet-encapsulated fluidic compositions to a microfluidic screening platform of the instant disclosure; applying electrocoalescence, thermal coalescence or acoustic coalescence to merge droplets in user-selected adjacent microwells into a single merged assay, across the array of microwells, thereby forming an array of at least 500 independent merged assays; and comparing merged assays selected from among the at least 500 independent merged assays with one another to identify attributes of the merged assays. In another aspect, the disclosure provides a microfluidic screening platform that includes: a top plate having an upper portion including a plurality of top plate through holes, a lower portion, and an inlet, wherein the inlet extends through both the upper portion and the lower portion; a bottom plate having an upper portion including a plurality of bottom plate through holes and a lower portion, wherein the lower portion includes an internal cut out; a glass substrate configured to seat on the upper portion of the bottom plate and cover the internal cut out; and a plurality of shafts corresponding to the plurality of top plate through holes and bottom plate through holes configured to mate the top plate to the bottom plate, wherein a droplet flow channel is defined by an upper surface of the glass substrate and a lower surface of the lower portion of the top plate when the top plate is mated to the bottom plate. In embodiments, a surface that includes a plurality of microwells, each of which is configured to hold at least one droplet (optionally a single droplet), contacts the lower surface of the lower portion of the top plate. Optionally, the surface that includes the plurality of microwells comprises PDMS (polydimethylsiloxane). In embodiments, each of the plurality of microwells is surrounded by one or more posts. In embodiments, a surface that includes a plurality of microwells, each of which is configured to hold at least one droplet (optionally a single droplet), includes a filter positioned between the inlet and the plurality of microwells. Another aspect of the instant disclosure provides a microfluidic screening platform including: at least one droplet input for receiving one or more sets of droplets, each set of droplets including individual droplets each individual droplet harboring a single type of bacteria and/or chemical compound (and/or a single type of combination thereof) or mixture, where the bacteria is Achromobacter spp. (e.g., Achromobacter denitrificans, Achromobacter xylosoxidans, Achromobacter ruhlandii); Actinomadura spp. (e.g., Actinomadura luteofluorescens, Actinomadura madurae, Actinomadura pelletieri, Actinomadura viridis); Agrobacterium spp. (e.g., Agrobacterium radiobacter, Agrobacterium luteun, Agrobacterium agile, Agrobacterium rubi); Arthrobacter spp. (e.g., Arthrobacter arilaitensis, Arthrobacter chlorophenolicus, Arthrobacter aurescens); Bacillus spp. (e.g., Bacillus cereus, Bacillus subtilis, Bacillus coagdans, Bacillus psychrosaccharolyticus, Bacillus amyloliquefaciens, Bacillus lentus, Bacillus circulans, Bacillus firmus); Burkholderia spp. (e.g., Burkholderia gladioli, Burkholderia plantarii, Burkholderia cepacia); Clostridium spp. (e.g., Clostridium orbiscindens, Clostridium formicaceticum); Escherichia coli; Ewingella spp. (e.g., Ewingella americana); Flavobacterium spp. (e.g., Flavobacterium flevense, Flavobacterium aquatile, Flavobacterium saccharophilum, Flavobacterium hydauis, Flavobacterium johnsoniae); Flexibacter spp. (e.g., Flexibacter flexilis, Flexibacter columnare); Herbaspirillum frisingense; Hyphomicrobium spp. (e.g., Hyphomicrobium aestuarii); Micromonospora spp. (e.g., Micromonospora rosaria, Micromonospora facile, Micromonospora zavarzinii, Micromonospora denitrificans); Mycobacterium spp. (e.g., Mycobacterium neoaurum); Nocardia spp. (e.g., Nocardia jiangxiensis, Nocardia miyunensis); Paenibacillus spp. (e.g., Paenibacillus macquariensis, Paenibacillus macerans, Paenibacillus alvei, Paenibacillus polymyxa, Paenibacillus chibensis); Pseudomonas spp. (e.g., Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas citronellolis, Pseudomonas chlororaphis, Pseudomonas aurantiaca, Pseudomonas pseudopalustris, Pseudomonas palustris, Pseudomonas syringae, Pseudomonas veronii, Pseudomonas aurantiaca); Ralstonia spp. (e.g., Ralstonia solanacearum, Ralstonia pickettii, Ralstonia syzygii); Rhodococcus spp. (e.g., Rhodococcus erythropolis, Rhodococcus rhodochrous); Serratia spp. (e.g., Serratia erratia liquefaciens); Sphingomonas spp. (e.g., Sphingomonas phingomonas phingomonas wittichii); Streptomyces spp. (e.g., Streptomyces lividans, Streptomyces coelicolor, Streptomyces tanashiensis, Streptomyces clavuligerus, Streptomyces griseus); and an array of microwells, where each microwell is capable of receiving an individual droplet. An additional aspect of the instant disclosure provides a microfluidic screening platform including: at least one droplet input for receiving one or more sets of droplets, each set of droplets including individual droplets each individual droplet harboring a single type of fungi and/or a chemical compound (and/or a single type of combination thereof) or mixture, where the fungi is Venturia, Aspergillus, Podosphaera, Erysiphe, Monilinia, Uncinula, Aureobasidium, Sclerophoma, Acremonium, Actinoplanes, Agaricus, Chrysosporium, Colletotrichum, Coprinus, Cryptococcus, Filibasidum, Humicola, Magnaporthe, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Phytophthora, Piromyces, Panerochaete, Pleurotus, Pythium, Schizophyllum, Talaromyces, Thermoascus, Thielava, Tolypocladium, Trichoderma, Hemileia, Rhizoctonia, Puccinia, Coniophora, Serpula, Poria, Uromyces, Gloeophyllum, Lentinus, Coriolus, Irpex, Mucor, Botrytis, Helminthosporium, Rhynchosporium, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia, Penicillium, Geotrichum, and/or Zymoseptoria; and an array of microwells, where each microwell is capable of receiving an individual droplet. Another aspect of the instant disclosure provides a microfluidic screening platform including: at least one droplet input for receiving one or more sets of droplets, each set of droplets including individual droplets each individual droplet harboring a single type of bacteria, fungi and/or chemical compound (and/or a single type of combination thereof) or mixture, where the bacteria is Achromobacter spp. (e.g., Achromobacter denitrificans, Achromobacter xylosoxidans, Achromobacter ruhlandii); Actinomaduru spp. (e.g., Actinomadura ctinomadura ctinomadura ctinomadura viridis); Agrobacterium spp. (e.g., Agrobacterium radiobacter, Agrobacterium luteum, Agrobacterium agile, Agrobacterium rubi); Arthrobacter spp. (e.g., Arthrobacter arilaitensis, Arthrobacter chlorophenolicus, Arthrobacter aurescens); Bacillus spp. (e.g., Bacillus cereus, Bacillus subtilis, Bacillus coagulans, Bacillus psychrosaccharolyticus, Bacillus anyloliquefaciens, Bacillus lentus, Bacillus circulans, Bacillus firmus); Burkholderia spp. (e.g., Burkholderia gladioli, Burkholderia plantarii, Burkholderia cepacia); Clostridium spp. (e.g., Clostridium orbiscindens, Clostridium formicaceticum); Escherichia coli; Ewingella spp. (e.g., Ewingella americana); Flavobacterium spp. (e.g., Flavobacterium flevense, Flavobacterium aquatile, Flavobacterium saccharophilum, Flavobacterium hydatis, Flamobacterium johnsoniae); Flexibacter spp. (e.g., Flexibacter flexilis, Flexibacter columnare); Herbaspirillum frisingense; Hyphomicrobium spp. (e.g., Hyphomicrobium aestuarii); Micromonospora spp. (e.g., Micromonospora icromonospora facile, Micromonospora icromonospora denitrificans); Mycobacterium spp. (e.g., Mycobacterium neoaurum); Nocardia spp. (e.g., Nocardia jiangxiensis, Nocardia miyunensis); Paenibacillus spp. (e.g., Paenibacillus macquariensis, Paenibacillus macerans, Paenibacillus alvei, Paenibacillus polymyxa, Paenibacillus chibensis); Pseudomonas spp. (e.g., Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas fluorescens, Pseudomonas citronellolis, Pseudomonas chlororaphis, Pseudomonas aurantiaca, Pseudomonas pseudopalustris, Pseudomonas palustris, Pseudomonas syringae, Pseudomonas veronii, Pseudomonas aurantiaca); Ralstonia spp. (e.g., Ralstonia solanacearum, Ralstonia pickettii, Ralstonia syzygii); Rhodococcus spp. (e.g., Rhodococcus erythropolis, Rhodococcus rhodochrous); Serratia spp. (e.g., Serratia erratia liquefaciens); Sphingomonas spp. (e.g., Sphingomonas phingomonas phingomonas wittichii); and/or Streptomyces spp. (e.g., Streptomyces lividans, Streptomyces coelicolor, Streptomyces tanashiensis, Streptomyces clavidigerus, Streptomyces griseus); where the fungi is Venturia, Aspergillus, Podosphaera, Erysiphe, Monilinia, Uncinula, Aureobasidium, Sclerophoma, Acremonium, Actinoplanes, Agaricus, Chrysosporiun, Colletotrichum, Coprinus, Cryptococcus, Filibasidum, Humicola, Magnaporthe, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Phytophthora, Piromyces, Panerochaete, Pleurotus, Pythium, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, Hemileia, Rhizoctonia, Puccinia, Coniophora, Serpula, Poria, Uromyces, Gloeophyllum, Lentinus, Coriolus, Irpex, Mucor, Botrytis, Helminthosporium, Rhynchosporium, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia, Penicillium, Geotrichum, and/or Zymoseptoria, optionally wherein the fungi is a filamentous fungi, e.g., Acremonium, Agaricus, Aspergillus, Aureobasidium, Chrysosporium, Coprinus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocallimastix, Neurospora, Paecilomyces, Penicillium, Piromyces, Panerochaete, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trichoderma, and/or Zymoseptoria; and an array of microwells, where each microwell is capable of receiving an individual droplet. In certain embodiments, a fungal biology/activity is evaluated. Optionally, the fungal biology/activity is a fungal growth cycle or behavior attribute. Optionally, the growth cycle or behavior attribute is sporulation, germination and/or formation of mycelium, and/or is expression of a gene associated with such growth cycle or behavior attribute. Optionally, a bacteria and/or chemical compound or mixture that suppresses germination and/or suppresses expression of gene relevant to germination is evaluated and/or identified. In some embodiments, image analysis is performed to quantify aspects of the shape, morphology and/or growth of microbes. Optionally, image analysis is performed to identify the shape and/or morphology of fungal spores, fungal filaments and/or other fungal characteristics. In certain aspects, it is further provided that individual droplets can be made and used in which each individual droplet harbors a discrete form of microbial and/or chemical compound combination or mixture, and such individual droplets and/or sets of individual droplets harboring a discrete form of microbial and/or chemical compound combination or mixture can be used as if they were a single set of droplets as provided for elsewhere herein. Definitions The term “microbe” refers to a member of a community of microorganisms that occur (sustainably or transiently) in and on, but not limited to, animals, plants, and soil. The term “microbe” comprises, but is not limited to, a eukaryote, archaea, a bacterium, and a virus (including bacterial viruses, i.e., phage). In particular, the term “microbe” described herein may be used for different strains of bacteria and algae. The term “combination of two or more microbes” refers to the presence of two or more microbes in physical proximity to one another (e.g., within the same well, merged droplet, etc.). Physical co-existence of the two (or more) microbes can be either in the same material or product or in physically connected products and/or can refer to the temporal co-administration or co-localization of the two (or more) microbes. As used herein, the term “microfluidic screening platform” may define a high-density array of microwells for cultivating at least one biological entity. The term “high density” may refer to a capability of a system or method to distribute a number of experiments within a constant area. A “microfluidic screening platform” may include a substrate with a series of functional layers. The series of functional layers may include a first functional layer defining a first array of experimental units (e.g., wells) and at least one subsequent functional layer defining a subsequent array of experimental units (e.g., microwells) in each experimental unit of the preceding functional layer. Each of the experimental units may be configured to receive and cultivate and/or screen biological entities and/or nutrients. In particular, systems, kits, apparatus, and methods described herein may be used for automated and/or high throughput combinatorial screening of different microbes. The term “high throughput” may refer to a capability of a system or method to enable quick performance of a very large number of experiments in parallel or in series. An example of a “high throughput” system may include automation equipment with cell biology techniques to prepare, incubate, and/or conduct a large number of chemical, genetic, pharmacological, optical, and/or imaging analyses to screen one or more biological entities for at least one of a metabolite, an enzyme, a protein, a nucleic acid, a phenotype, a mutation, a metabolic pathway, a gene, an adaptation, and a capability, as discussed herein. According to some embodiments, “high throughput” may refer to simultaneous or near simultaneous experiments on a scale ranging from at least about 96 experiments to at least about 10,000,000 experiments. The term “low-pass filter,” as used herein, refers to a physical enmity capable of disrupting or preventing the passage of droplets of a size that exceeds a predefined size. In particular embodiments, the term “low-pass filter” as exemplified herein refers to internal posts arranged around the periphery of a microwell and that are capable of disrupting or preventing the entry of large droplets into individual microwells. The term “high-pass filter,” as used herein, refers to a physical entity that disrupts or prevents the passage of droplets below a predefined size. In particular embodiments, the term “high-pass filter” as exemplified herein (as a pre-filter) refers to a series of channels/moat-like engravings of a defined size designed to trap small droplets during fluid flow. The term “chemical compound”, as used herein refers to any non-microbe agent (alternatively referred to as a “test agent”) optionally a non-living agent—capable of being included in droplets of the instant disclosure. Exemplary chemical compounds for use with the instant disclosure include, but are not limited to, macromolecules (e.g., proteins, oligonucleotides, antibodies and/or fragments thereof, etc.) and small molecules. In certain embodiments, libraries of test chemicals can be used in the present disclosure, optionally from which candidate molecule(s) can be selected during use of the microfluidic platform of the instant disclosure. In some embodiments, test compounds are small molecules, in other embodiments they are members of randomer or combinatorial sequence or shape libraries, optionally comprising sequenceable oligomers and/or other macromolecules. In some embodiments, the candidate chemicals are conjugates, chimera and/or modular constructs. In certain embodiments, exemplary chemical compounds or mixtures can also include complex mixtures of chemicals and/or microbes, for example natural products and/or spent or conditioned media libraries from other microbes, including extracts from natural sources (e.g., extracts from bodily fluids, plants, soil)—including fractionated extracts (i.e., eluents from chemical fractionation of extracts from natural sources), filtered natural fluids (e.g. urine, saliva, blood, etc.), and other such natural products. In some specifically contemplated embodiments, washing of soil in media to separate microbes and solids can be performed, with the wash then directly added to droplets (with such wash containing a complex mixture of microbes and chemicals, not a single type of microbe or a single chemical compound), or such a wash could even be fractionated using, e.g., HPLC or other separation method, with droplets made from individual fractions and introduced to the instant kChip. Thus, mixtures of compounds, not only pure compounds, are expressly contemplated for use as chemical compounds or mixtures in certain embodiments of the instant disclosure. The term “small molecule” refers to compounds, optionally organic compounds, with a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, peptides, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, e.g., up to about 4000, preferably up to 3000 Da, more preferably up to 2000 Da, even more preferably up to about 1000 Da, e.g., up to about 900, 800, 700, 600 or up to about 500 Da. Small molecules typically have a molecular weight of 100, 200, or 300 Daltons or more. Small molecules include, but are not limited to, inorganic molecules, organic molecules, organic molecules containing an inorganic component, molecules comprising a radioactive atom and/or fluor, synthetic molecules, peptide mimetics, and antibody mimetics. As used herein, “changed as compared to a control” sample or subject is understood as having a level of the analytic or diagnostic or therapeutic indicator to be detected at a level that is statistically different than a sample from a normal, untreated, or control sample. Control samples include, for example, cells in culture, one or more laboratory test animals, or one or more human subjects. Methods to select and test control samples are within the ability of those in the art. An analytic substance can be a naturally occurring substance that is characteristically expressed or produced by the cell or organism (e.g., pathogenic bacteria, antibodies, pathogenic peptides or particles, and the like) or a substance produced by a reporter construct (e.g., β-galactosidase or luciferase). Depending on the method used for detection the amount and measurement of the change can vary. Determination of statistical significance is within the ability of those skilled in the art. As used herein, the terms “comprises,” “comprising,” “containing” and “having” and the like are open-ended as defined by U.S. patent law and can mean “includes,” “including,” and the like; “consisting essentially of” or “consists essentially” likewise has the meaning ascribed in U.S. patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments. As used herein, “detecting,” “detection,” and the like are understood to mean that an assay is performed to determine one or more characteristics of a sample, e.g. identifying the presence, absence or amount of the analyte to be detected. For example, detection can include identification of a specific analyte in a sample or an activity of an agent in a sample. Detection can include the determination of the presence of nucleic acid, protein (e.g., antibody, cytokine, and the like) by PCR, immunoassay (e.g., ELISA), microscopy, pathogen challenge, and the like. The amount of analyte or activity detected in the sample can be none or below the level of detection of the assay or method. By “enhances” is meant a positive alteration of at least 10%, 25%, 50%, 75%, 100%, or any number therebetween. “Obtaining” is understood herein as manufacturing, purchasing, synthesizing, isolating, purifying, or otherwise coming into possession of. Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, as well as all intervening decimal values between the aforementioned integers such as, for example, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, and 1.9. With respect to sub-ranges, “nested sub-ranges” that extend from either end point of the range are specifically contemplated. For example, a nested sub-range of an exemplary range of 1 to 50 may comprise 1 to 10, 1 to 20, 1 to 30, and 1 to 40 in one direction, or 50 to 40, 50 to 30, 50 to 20, and 50 to 10 in the other direction. By “reduces” is meant a negative alteration of at least 10%/o, 25%, 50%, 75%, 100%, or any number therebetween. By “reference” is meant a standard or control condition. A “sample” as used herein refers to a biological material that is isolated from its environment (e.g., microbes obtained and isolated from soil, blood or tissue from an animal, cells, or conditioned media from tissue culture). As used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a gene” is a reference to one or more genes and includes equivalents thereof known to those skilled in the art, and so forth. Unless specifically stated or obvious from context, as used herein, the term “or” is understood to be inclusive. Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2/o, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein can be modified by the term about. The recitation of an embodiment for a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof. Other definitions appear in context throughout this disclosure. Any therapeutic agents, compositions, or methods provided herein can be combined with one or more of any of the other therapeutic agents, compositions, and methods provided herein. Where applicable or not specifically disclaimed, any one of the embodiments described herein are contemplated to be able to combine with any other one or more embodiments, even though the embodiments are described under different aspects of the disclosure. These and other embodiments are disclosed and/or encompassed by, the following Detailed Description. BRIEF DESCRIPTION OF THE DRAWINGS The following detailed description, given by way of example, but not intended to limit the disclosure solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings, in which: FIGS. 1A-1D depict how the kChip of the instant disclosure enables massively parallel construction of microbial communities. FIG. 1A shows how 1 nL droplets were first produced. Each droplet contained a color code (a specific ratio of three fluorescent dyes) that maps to a corresponding input. After they were pooled, droplets were loaded onto the kChip, where they randomly grouped into microwells. The microwells were designed to group precisely k droplets. The kChip was imaged to identify the contents of each microwell from the droplet color codes. Droplets were then merged within their respective microwells via exposure to an alternating-current electric field, which generated parallel synthetic communities. Community phenotypes could be tracked via optical assays, including fluorescent protein expression and respiration-driven reduction of resazurin to the fluorescent product resorufin. Solid microwell borders=conceptual microwell outlines. Dotted microwell borders=microscopy images where borders were not visible. FIG. 1B shows how microwell types were produced by encircling sets of internals posts (see FIGS. 6A-6D below). Examples of micrographs show grouping and merging of droplets for these microwell types. FIG. 1C depicts a general schematic of kChip. Pooled droplets were dispensed into a kChip-loading apparatus (see FIGS. 5A-5D below). Any small droplets were first filtered out via moat-like traps (“Small droplet size filter”, 90 μm wide) prior to droplet grouping. Specific microwell arrangements can be determined by the user and can include ≥1 microwell type per kChip. Dotted lines=user-determined borders between different microwell types. FIG. 1D shows how microwells were densely packed on the kChip (FIGS. 6A-6D), with k dictating microwell density. A single microwell type can be arrayed across a kChip (“Full kChip”). For the screening application reported in FIG. 3 and FIG. 4, “k={1:7;19} Chip” was generated and it included different microwell types arranged in parallel. FIGS. 2A-2F show how carbon utilization profiles of labeled and unlabeled strains were measured on k=2 chips. FIG. 2A summarizes how droplet libraries could be made from a library of fluorescently labeled strains (see FIG. 28 below) and a library of carbon sources (see FIG. 33 below). The ability of each strain to grow on each carbon source could be measured by monitoring microwells that received one microbe-containing droplet and one carbon source-containing droplet. FIG. 2B is a micrograph of grouped droplets containing color codes and assay result. FIG. 2C shows how fluorescence was measured for a panel of 10 fluorescent strains (starting OD600=0.02) across 15 conditions (13 carbon donna73@example.com w/v+1 glucose replicate control+1 no-carbon condition) in k=2 Chip microwells (21° C., no shaking) as well 200-μL cultures in 96-well plates (21° C., 220 RPM). Heatmaps show the relative signal at 50 hours, with interleaved columns corresponding to the kChip and 96-well plates (Pearson r=0.868) (full time course in FIG. 10B below). FIG. 2D shows how the dye resazurin was added to carbon source media prior to droplet production (post-merge concentration 40 μM) to measure growth of unlabeled strains. Resazurin gets reduced to the fluorescent product resorufin in the presence of metabolically active cells (growth is therefore monitored via resazurin's respiration-driven reduction to resorufin). FIG. 2E is a micrograph of grouped droplets containing color codes and resazurin assay result. FIG. 2F summarizes the resazurin signal (fluorescence due to resorufin accumulation) obtained for three strains (starting OD600=0.005) across four carbon source conditions in k=2 Chip microwells (21° C., no shaking) and compared to OD600 measurements from 200-μL cultures in 96-well plates (21° C., 220 RPM). Heatmaps show signal at 22 hours (Pearson r=0.969) (full time course in FIG. 12B below). In FIG. 2C and FIG. 2F, relative signal for each row was obtained by normalizing to the maximum across all carbon sources and timepoints after background subtraction. FIGS. 3A-3G show how high-throughput kChip screening identified Hf-promoting compositions that were robust to carbon source and additional bacterial isolates. FIG. 3A shows a screen schematic to identify Hf-promoting compositions. Communities were constructed whereby Hf-GFP represents half of the starting biomass (starting Hf-GFP OD600=0.02) and the other half was divided evenly among 1 to 7 or 19 soil isolate inputs (starting total isolate OD600=0.02 if no control droplets present). Each of these communities was constructed in one of six media that each contained a single carbon source. These carbon sources enabled Hf-GFP monoculture growth to varying extents (bars=Hf-GFP yield at 72 hrs in k=1 microwells where droplet received no isolate; error bars=standard deviation). FIG. 3B summarizes the screening strategy. Each droplet received Hf-GFP, a single isolate or control, and a single carbon source. Droplets containing the same carbon source were pooled and loaded onto the same kChip (six kChips in total, at 21° C., no shaking). After droplet merging, Hf-GFP yield was measured (at 24, 48, 72 hr) in each community/carbon source environment. This analysis differentiated between a “composition” as a subset of size s embedded in larger “communities” of size k that contained the composition+(k−s) additional isolates. FIG. 3C shows the total number of assay points collected for different values of 19 k (about evenly divided among the six kChips, see FIG. 35 below). FIG. 3D shows the ranked Hf-GFP yield at 72 hr for all communities (s=k) constructed. Median calculated when community replicated >1 time; error bar=standard error of the mean; dotted line=Hf-GFP yield in monoculture. FIG. 3E is an example s=k=2 pair of isolates with a facilitative effect on Hf-GFP that was not robust to carbon source. FIG. 3F is an example s=2 composition with a facilitative effect on Hf-GFP in galactose that was not robust to community context. FIG. 3G is a graph of Hf-GFP robustness against Hf-GFP yield. For compositions represented ≥30 times across all carbon sources (only k=1, 2, 3 compositions met this criteria), median Hf-GFP yield (x-axis) quantifies the effect of the composition on Hf-GFP across carbon sources. The 10th percentile of Hf-GFP for all communities containing a given composition (y-axis) quantifies a robustness to community context across all carbon sources. (Insets) Each data point represents Hf-GFP yield in a single microwell where the color indicates carbon source (corresponding to FIG. 3A). The left distribution shows Hf-GFP yield when the given composition was present (used to calculate x-axis yield metric). The right distribution shows Hf-GFP yield for all communities containing the composition (used to calculate y-axis robustness metric). Blue points=composition contains at least BuC. Brown points=composition contains at least [BaL+Ra]. Dotted line=1500 GFP counts, a minimal viable and detectable signal from Hf-GFP (one standard deviation above Hf-GFP yield in sucrose). FIGS. 4A-4D show how facilitation increased with community richness and was driven by a few strains. FIG. 4A shows that in a medium containing sucrose, lactose, or raffinose, Hf-GFP yield increased with community richness. Colored distributions=median Hf-GFP yields for all unique compositions at given k (i.e. all droplets in a given combination contain different strains). Gray data point=median of distribution. Outlined distributions=medians of 100 bootstrap-resampled datasets at each k, whereby the Hf-GFP yield dataset for each k was resampled with replacement (with resampling sample size equal to the actual sampling size), and a median of the resampled data was calculated each time. FIG. 4B shows how primary facilitators (outlined in orange) were classified as the isolates increasing Hf-GFP yield by ≥100 GFP counts (a.f.u.). FIG. 4C presents graphs that ascertained that the presence of 21 primary facilitator was necessary and typically sufficient to enable Hf-GFP growth and drive a facilitative effect when additional isolates were present. Colored distributions=Hf-GFP growth in communities possessing ≥1 primary facilitators. Gray distributions=Hf-GFP yield in communities with no primary facilitators. FIG. 4D presents graphs and data from a resazurin assay which was conducted on a separate k=2 Chip in parallel with the screen to measure growth rate of each isolate (see FIG. 24 below). The subset of isolates that grew on a given carbon source (defined at ≥1 doubling of resorufin fluorescence by 36 hr) corresponded with the subsets of isolates identified as primary facilitators. FIGS. 5A-5I show how a loading apparatus assists droplet loading onto kChip. FIG. 5A shows how kChip microwells are loaded with droplets by suspending the kChip within a loading apparatus. This apparatus consists of an acrylic housing and hydrophobic glass substrate. The kChip naturally forms a seal with the top piece of acrylic. In its unclamped state, a flow space (˜500-700 μm) is maintained between by a repulsive magnetic force such that droplets can flow under the kChip. Tilting the apparatus moves droplets through the flow space, and random sets of droplets spontaneously group within microwells. FIG. 5B is a photograph of the kChip loading apparatus. FIG. 5C is a diagram of the side-view of loading apparatus and droplet loading procedure (not to scale). FIG. 5D shows a cross-sectional side view of a microfluidic screening platform according to an exemplary embodiment of the disclosure. FIG. 5E shows a bottom view of a lower surface of a top plate of a microfluidic screening platform including a plurality of microwells according to an exemplary embodiment of the disclosure. FIG. 5F and FIG. 5G show a top view and a side view, respectively, of a top plate of a microfluidic screening platform according to an exemplary embodiment of the disclosure. FIG. 5H and FIG. 5I show a top view and a side view, respectively, of a bottom plate of a microfluidic screening platform according to an exemplary embodiment of the disclosure. FIGS. 6A-6D show an exemplary kChip design strategy. FIG. 6A shows how triangular posts were arrayed such that each hexagonal arrangement enclosed a space optimized for a single droplet. The diameter of the enclosed space used in all kChip microwell types was set to 148.2 μm, which was optimized for 135-μm droplets, the mean droplet size of minimal medium (MM) droplets made with 0.05% BSA added to the medium and 2% stabilizing fluorosurfactant (see FIGS. 28A-28C below). FIG. 6B shows that microwell shapes were carved by encircling internal posts to achieve the desired k. These microwell designs are modular and generalizable: increasing the size of the boundary around posts produces microwells that group more droplets. FIG. 6C shows that each microwell design was arrayed with ˜50 μm inter-microwell spacing. FIG. 6D shows that specific microwell arrangements on a kChip are determined by the user and can include 21 microwell type per kChip. A given kChip can have entirely one type (“Full kChip”), e.g. all k=2 microwells (e.g. experiments discussed in FIGS. 2A-2F above) or an assortment of different types, e.g. subsets of k={1:7;19} microwells (e.g. the Hf-GFP facilitation screen discussed in FIGS. 3A-3G above). All exemplified kChips also included a series of 30 90-μm wide moat-like engravings (“slots”) designed to make up a small droplet size filter. In exemplified kChips, hese slots are spaced 50 μm apart from each other and 400 μm from the onset of the microwells. The slots are inset 3 mm from the edge of the kChip. FIGS. 7A to 7D show that microwell geometry and internal posts promoted precise droplet grouping without affecting microbial growth. FIG. 7A is a ffluorescence micrograph (10× magnification) highlighting how internal posts produce correct droplet grouping. Presumably, internal posts enable low-pass size filtering and spatial confinement of droplets within microwells. FIG. 7B shows a graph that depicts the percentage of correct grouping observed for kChips with and without internal posts. Four kChips were loaded that included internal posts (Chips #1-4) and two that did not (Chips #5-6). Over 90%, of microwells filled correctly for all
{'application_number': '<application-reference appl-type="utility">\n<document-id>\n<country>US</country>\n<doc-number>17607780</doc-number>\n<date>20200430</date>\n</document-id>\n</application-reference>', 'publication_number': '<publication-reference>\n<document-id>\n<country>US</country>\n<doc-number>20220228190</doc-number>\n<kind>A1</kind>\n<date>20220721</date>\n</document-id>\n</publication-reference>', 'source_file': './application/2022/ipa220721.xml', 'source_data': 'USPTO-Application'}